Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2018-A01699-46 | Other Identifier | ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The implementation of pharmaceutical consultations in the city or at the hospital could modify the occurrence of exacerbations related to chronic obstructive pulmonary disease after return of the patient to his home.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control group | No Intervention | ||
| Experimental group from the hospital | Experimental |
| |
| Experimental group from the city | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pharmaceutical consultation at the hospital | Other | During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of exacerbation events | Exacerbation events will be defined as any episode of increased respiratory symptoms, especially dyspnea, cough and sputum production, and increased sputum purulence. | Month 3 |
| Number of exacerbation events | Exacerbation events will be defined as any episode of increased respiratory symptoms, especially dyspnea, cough and sputum production, and increased sputum purulence. | Month 6 |
| Number of exacerbation events | Exacerbation events will be defined as any episode of increased respiratory symptoms, especially dyspnea, cough and sputum production, and increased sputum purulence. | Month 9 |
| Number of exacerbation events | Exacerbation events will be defined as any episode of increased respiratory symptoms, especially dyspnea, cough and sputum production, and increased sputum purulence. | Month 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Number of visits to the attending physician | Month 3 | |
| Number of visits to the attending physician | Month 6 | |
| Number of visits to the attending physician |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nimes University Hospital | Nîmes | 30029 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38269046 | Result | Hachemi D, Leguelinel-Blache G, Bouvet S, Roux-Marson C, Plouvier N, Kinowski JM, Castelli C, Dubois F. Clinical impact of pharmaceutical consultations in patients treated for chronic obstructive pulmonary disease: Study protocol for a randomized controlled trial (BPCObs study). Contemp Clin Trials Commun. 2023 Dec 20;37:101249. doi: 10.1016/j.conctc.2023.101249. eCollection 2024 Feb. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Pharmaceutical consultation at the pharmacy | Other | During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use. |
|
| Follow-up pharmaceutical consultation at the pharmacy | Other | During 10 minutes, the patient will get more information about his chronic obstructive pulmonary disease treatments and their use. |
|
| Month 9 |
| Number of visits to the attending physician | Month 12 |
| Number of visits to the pulmonologist | Month 3 |
| Number of visits to the pulmonologist | Month 6 |
| Number of visits to the pulmonologist | Month 9 |
| Number of visits to the pulmonologist | Month 12 |
| Number of visits to the hospital emergency service | Month 3 |
| Number of visits to the hospital emergency service | Month 6 |
| Number of visits to the hospital emergency service | Month 9 |
| Number of visits to the hospital emergency service | Month 12 |
| Number of hospitalisation events | Month 3 |
| Number of hospitalisation events | Month 6 |
| Number of hospitalisation events | Month 9 |
| Number of hospitalisation events | Month 12 |
| Medication Possession Ratio | unit = percent | 12 months |
| Usability score of devices | Score between 0 and 3 | Month 3 |
| Usability score of devices | Score between 0 and 3 | Month 6 |
| Usability score of devices | Score between 0 and 3 | Month 9 |
| Usability score of devices | Score between 0 and 3 | Month 12 |
| Quality of life questionnaire | The quality of life questionnaire BPCO-VQ11 is composed of 11 items. Each item is scored in a 5 point scale. | Month 1 |
| Quality of life questionnaire | The quality of life questionnaire BPCO-VQ11 is composed of 11 items. Each item is scored in a 5 point scale. | Month 6 |
| Quality of life questionnaire | The quality of life questionnaire BPCO-VQ11 is composed with11 items. Each item is scored in a 5 point scale. | Month 12 |
| device usage learning curve | 12 months |
| satisfaction questionnaire | This questionnaire is composed with 4 questions. Each item is scored in a 4 point scale. | Month 12 |
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided